View Older Stories View More Recent Stories

Jan 12, 2026 03:47PM Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
Jan 12, 2026 08:07AM Cogent Biosciences outlines 2026 milestones for bezuclastinib drug applications
Jan 7, 2026 10:15AM Cogent Biosciences (COGT) call put ratio 3.4 calls to 1 put as share price up 2.1%
Jan 7, 2026 12:41AM UBS Starts Cogent (COGT) at Buy
Jan 6, 2026 06:42AM Cogent (COGT) PT Raised to $52 at H.C. Wainwright
Dec 30, 2025 09:46AM Raymond James on Cogent (COGT): 'We anticipate shares will continue to work in 2026'
Dec 30, 2025 08:02AM Cogent Biosciences submits drug application for systemic mastocytosis
Dec 8, 2025 02:11PM Cogent (COGT) PT Lowered to $49 at Leerink Partners
Dec 8, 2025 08:38AM Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
Dec 8, 2025 07:35AM Cogent's (COGT) Bezuclastinib Up For Approval in 2026 - Stifel
Dec 8, 2025 07:31AM Cogent Biosciences reports positive APEX trial results for bezuclastinib
Dec 8, 2025 02:54AM Cogent Biosciences presents full SUMMIT trial results for bezuclastinib
Dec 3, 2025 10:52AM Increasing unusual call option volume: IRBT BOX CAR WRAP PSTG AEVA GENI HTGC COGT
Dec 2, 2025 10:19AM Increasing unusual call option volume: BRR COGT JANX MDB EH KMB TSEM UNFI SIG FRPT TXG
Nov 11, 2025 04:27AM Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite'
Nov 10, 2025 01:18PM Cogent (COGT) PT Raised to $50 at Leerink Partners
Nov 10, 2025 10:54AM Stifel Upgrades Cogent (COGT) to Buy
Nov 10, 2025 10:10AM Wedbush Upgrades Cogent (COGT) to Outperform
Nov 10, 2025 10:02AM Stifel Reiterates Hold Rating on Cogent (COGT)
Nov 7, 2025 04:53PM Cogent Biosciences (COGT) files mixed shelf
Oct 24, 2025 12:30PM Cogent Biosciences presents KRAS inhibitor data at cancer conference
Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
Oct 15, 2025 04:10PM Stifel Starts Cogent (COGT) at Hold
Sep 23, 2025 12:00PM This biotech stock is a Top Pick at Raymond James
Sep 22, 2025 05:06AM Raymond James Reiterates Strong Buy Rating on Cogent (COGT), 'Remains a Top Pick After CEO Fireside Chat'
Sep 16, 2025 06:44AM Raymond James Adjust Analyst Current Favorites List
Aug 25, 2025 07:16AM Cogent (COGT) PT Raised to $20 at Guggenheim
Aug 5, 2025 03:26PM Cogent Biosciences (COGT) spreader of November 13 and 20 calls
Aug 5, 2025 10:20AM Increasing unusual call option volume: COGT OMI AIP TDW AMCR ULCC DOCN PTIR
Jul 18, 2025 04:56AM Cogent (COGT) PT Raised to $22 at Citi, Removes 30d Upside Catalyst Watch
Jul 10, 2025 04:02PM Cogent Biosciences completes upsized $230 million public offering
Jul 9, 2025 05:59AM Cogent Biosciences prices $200 million stock offering at $9 per share
Jul 8, 2025 04:49PM Cogent Biosciences announces $150 million public stock offering
Jul 8, 2025 04:49PM After-hours movers: Mobileye, RxSight, Cogent Biosciences
Jul 7, 2025 10:43AM Cogent (COGT) PT Raised to $28 at Jefferies
Jul 7, 2025 10:23AM Cogent (COGT) PT Raised to $18 at Leerink Partners
Jul 7, 2025 07:07AM Cogent Biosciences (COGT) reports positive results from mastocytosis drug trial
Jun 30, 2025 05:02AM Citi Opens 30d Upside Catalyst Watch on Cogent (COGT)
Jun 16, 2025 09:05AM Piper Sandler Reiterates OW Rating on Cogent (COGT) Ahead of Pivotal Non-AdvSM Data
Jun 11, 2025 08:09AM Cogent Biosciences (COGT) Secures up to $400 Million in Non-Dilutive Financing
May 21, 2025 06:38AM Cogent (COGT) PT Lowered to $12 at H.C. Wainwright
May 1, 2025 02:36PM Cogent Biosciences (COGT) spreader of 10K contracts of August 5 and 10 calls
Mar 7, 2025 07:09AM Scotiabank Starts Cogent (COGT) at Sector Outperform
Feb 25, 2025 11:57AM Jefferies Reiterates Buy Rating on Cogent (COGT)
Jan 14, 2025 06:43AM Cogent (COGT) PT Lowered to $14 at H.C. Wainwright
Jan 13, 2025 08:15AM Cogent Biosciences (COGT) Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 9, 2024 07:06AM Cogent Biosciences (COGT) Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Nov 25, 2024 07:52AM Piper Sandler Reiterates Overweight Rating on Cogent (COGT)
Nov 13, 2024 07:11AM Cogent (COGT) PT Lowered to $15 at Needham
View More Recent Stories View Older Stories